Browse TRIP11

Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus, cis-Golgi network membrane Peripheral membrane protein Cytoplasm, cytoskeleton Note=Associates with the ends of centrosome-nucleated microtubules.
Domain -
Function

Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine and enhances THRB-modulated transcription. Golgi auto-antigen; probably involved in maintaining cis-Golgi structure.

> Gene Ontology
 
Biological Process GO:0000042 protein targeting to Golgi
GO:0000301 retrograde transport, vesicle recycling within Golgi
GO:0001501 skeletal system development
GO:0002062 chondrocyte differentiation
GO:0003205 cardiac chamber development
GO:0003231 cardiac ventricle development
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0003413 chondrocyte differentiation involved in endochondral bone morphogenesis
GO:0006486 protein glycosylation
GO:0006891 intra-Golgi vesicle-mediated transport
GO:0007030 Golgi organization
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0034067 protein localization to Golgi apparatus
GO:0042490 mechanoreceptor differentiation
GO:0043413 macromolecule glycosylation
GO:0043583 ear development
GO:0048193 Golgi vesicle transport
GO:0048705 skeletal system morphogenesis
GO:0048839 inner ear development
GO:0051216 cartilage development
GO:0060113 inner ear receptor cell differentiation
GO:0060119 inner ear receptor cell development
GO:0060122 inner ear receptor stereocilium organization
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0060351 cartilage development involved in endochondral bone morphogenesis
GO:0061448 connective tissue development
GO:0070085 glycosylation
GO:0072600 establishment of protein localization to Golgi
Molecular Function GO:0003713 transcription coactivator activity
Cellular Component GO:0001669 acrosomal vesicle
GO:0002079 inner acrosomal membrane
GO:0002080 acrosomal membrane
GO:0002081 outer acrosomal membrane
GO:0005801 cis-Golgi network
GO:0030133 transport vesicle
GO:0030141 secretory granule
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0097223 sperm part
GO:0098589 membrane region
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5617833: Cilium Assembly
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-6811438: Intra-Golgi traffic
R-HSA-5620924: Intraflagellar transport
R-HSA-199991: Membrane Trafficking
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRIP11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRIP11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.11; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRIP11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1760.578
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1780.872
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1740.839
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1080.716
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1160.963
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3930.904
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1570.667
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2320.885
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.070.969
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.360.682
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1390.337
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0240.67
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRIP11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRIP11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRIP11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRIP11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRIP11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRIP11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRIP11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRIP11
Namethyroid hormone receptor interactor 11
Aliases CEV14; Trip230; GMAP-210; GMAP210; ACG1A; TRIP-11; Golgi-microtubule-associated protein of 210 kDa; TR-inter ......
Chromosomal Location14q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRIP11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.